Across TCGA pan-cancer cohorts, ZNF652 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ZNF652’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ZNF652 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF652 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where ZNF652 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF652 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+0.452	<.001	9	view →
CCRCC	Male	III,IV	−0.290	<.001	8	view →
LSCC	All	II,III,IV	+0.355	<.001	7	view →
PDAC	Male	IV	−0.300	.014	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF652 RNA expression & survival · all ZNF652 data types